Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Sponsor: Bristol-Myers Squibb
Study ID: NCT06258668
Status: Recruiting

Apply to this trial

Conditions

Moderate-to-severe Plaque Psoriasis

Eligibility Criteria

Sex: ALL
Age: 19 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Deucravacitinib — DRUG
As per product label

Study Details

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Key Dates

Start date: Aug 21, 2024
Status verified: Nov 2024
Primary completion: Sep 30, 2028
Completion: Sep 30, 2028

Study Design

Enrollment: 505 participants (estimated)

Arms

Arm: Participants diagnosed with moderate-to-severe plaque psoriasis

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 24 weeks from treatment initiation ]

Central Contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
[email protected]
First line of the email MUST contain NCT # and Site #.